Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics is a biotechnology company based in San Diego, California, that develops targeted therapies for cancer. Its RedTail platform uses an engineered oncolytic vaccinia virus designed for systemic delivery to metastatic tumor sites. The platform’s lead candidate, CLD-401, is designed to deliver IL-15 superagonist to the tumor microenvironment. Calidi also develops stem cell-based oncolytic virus therapies through its SuperNova and NeuroNova platforms. SuperNova’s CLD-201 targets solid tumors, including breast cancer, sarcoma and head and neck cancer. NeuroNova’s CLD-101 targets newly diagnosed and recurrent high grade glioma. City of Hope conducts clinical studies of CLD-101 for recurrent disease, while Northwestern University has an open IND for a Phase 1b/2 trial for newly diagnosed disease. Calidi has limited sales, marketing and commercial product distribution capabilities.
No SEC Form 4 filings for $CLDI in the last 30 days.
See all $CLDI insider activity →Calidi Biotherapeutics reported no product sales in Q3 2026. Net loss narrowed to $3.65M from $10.82M YoY, with EPS at ($1.47). R&D costs rose, while G&A expenses fell. Other income increased due to a German research refund and fair-value gains. The company plans to cut 67% of headcount, expecting $3M in annual savings.
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Continued to advance the development of CLD-401 towards the clinic - Presented new CLD-401 data and in situ TCE platform advances at the ESMO Congress 2026 - Received
Calidi Biotherapeutics (CLDI) will present preclinical data at ESMO 2026 on CLD-401, CLD-501, and CLD-502, showing tumor eradication in mice and T-cell cytotoxicity. The company is in IND-enabling studies for CLD-401, with potential catalysts including IND filing and first-in-human data.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CLDI (Calidi Biotherapeutics, Inc.). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.
Recent CLDI coverage spans earnings, corporate actions and financial news.
The earnings beat loss expectations and announce cost cuts, likely providing modest upside pressure.
Near-term sentiment likely improves on the financing update and conference preclinical readouts, but cash burn and runway remain key overhangs.
First disclosure of preclinical results may spark investor interest ahead of IND filing.
The compliance notice creates immediate downside risk and potential delisting pressure.
Potential delisting risk could pressure the stock lower; compliance plan may stabilize price if satisfactory.
AlphAI scores every news story that mentions CLDI with an AI model for sentiment and relevance, and aggregates insider trades from Calidi Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Calidi Biotherapeutics reported no product sales in Q3 2026. Net loss narrowed to $3.65M from $10.82M YoY, with EPS at ($1.47). R&D costs rose, while G&A expenses fell. Other income increased due to a German research refund and fair-value gains. The company plans to cut 67% of headcount, expecting $3M in annual savings.
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Continued to advance the development of CLD-401 towards the clinic - Presented new CLD-401 data and in situ TCE platform advances at the ESMO Congress 2026 - Received
Calidi Biotherapeutics (CLDI) will present preclinical data at ESMO 2026 on CLD-401, CLD-501, and CLD-502, showing tumor eradication in mice and T-cell cytotoxicity. The company is in IND-enabling studies for CLD-401, with potential catalysts including IND filing and first-in-human data.
Calidi Biotherapeutics (CLDI) received a non-compliance notice from NYSE American for having less than $4M in stockholders' equity. The company must submit a plan by October 21, 2026, to regain compliance by March 21, 2028. CLDI shares fell 5.83% to $1.13 on Friday.
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency SAN DIEGO, September 25, 2026 – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the developm
Calidi Biotherapeutics received a NYSE American compliance notice for not meeting the $4M minimum stockholders' equity requirement. The stock will continue trading with a '.BC' designation. The company has until 2028 to submit a compliance plan and regain compliance. Despite the notice, the stock rose nearly 4% in after-hours trading.
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering SAN DIEGO, September 17, 2026 – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines,
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting fi
Calidi Biotherapeutics (NYSE: CLDI) shares rose after the company recapped 2026 progress and outlined upcoming milestones. Calidi said it held a successful pre-IND meeting with the FDA for CLD-401, discussed pharmacology, toxicology, CMC and phase I strategy, and is advancing in situ TCEs. It also added Corsee Sanders to the board and cut debt and G&A by about $1M in 1Q26 vs 1Q25.
Calidi Biotherapeutics (NYSE American: CLDI) reported a positive US FDA pre-IND outcome for CLD-401, agreeing on pharmacology, toxicology, CMC and phase I protocol strategy. The company targets first patient dosing in Q1 2027 and expects first data in Q2 2027. It also cited new RedTail in situ TCE data, added a board member, and cut G&A by about $1M from Q1 2025 to Q1 2026.
